Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.
Loi S, Salgado R, Curigliano G, Romero Díaz RI, Delaloge S, Rojas García CI, Kok M, Saura C, Harbeck N, Mittendorf EA, Yardley DA, Suárez Zaizar A, Caminos FR, Ungureanu A, Reinoso-Toledo JG, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu JQ, Pusztai L, McArthur H
- DOI
- 10.1038/s41591-024-03414-8
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-21
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/aae1b556-5a53-4eb7-a982-6ed5a3fa2061 is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×3−1.5★
- ClaimsOverstated claim ×2−1★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- ReportingData & code availability partially met−0.25★
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary endpoint is pathological complete response (pCR), a surrogate for long-term clinical outcomes such as event-free survival (EFS). The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking pCR to EFS in this specific setting; it only mentions that pCR is associated with improved long-term outcomes in ER+/HER2− BC, but this is not a validated surrogate for the efficacy claim.
“The primary endpoint of pCR was significantly higher in the nivolumab arm compared with placebo (24.5% versus 13.8%; P = 0.0021)”
- 02Treatment effect not shown to be clinically meaningful
The effect size is reported as an absolute difference of 10.7% in pCR rates (24.5% vs 13.8%), which is statistically significant but not anchored to a minimal clinically important difference or to long-term clinical benefit. The paper acknowledges that the study is underpowered for EFS and that follow-up is too short to draw conclusions, so the clinical meaningfulness of the pCR improvement is not established.
“Because of its early termination, the study was significantly underpowered for event-free survival (EFS), and median follow-up for EFS in the mITT population at reporting was premature at 19 months, with a low number of events observed.”
- 03Conclusion reaches beyond the evidence
The results suggest a new treatment paradigm that emphasizes the role of immunotherapy in luminal disease.
“These findings reshape our understanding of this disease in the context of T cell immunosurveillance and immunotherapy response in luminal disease.”
DiscussionFind in source - 04Conclusion reaches beyond the evidence
The results suggest a new treatment paradigm emphasizing the role of immunotherapy in luminal disease.
“These results represent a new milestone in the neoadjuvant treatment of ER+/HER2− BC”
DiscussionFind in source
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted and well-reported phase 3 randomized trial with strong methodology across most dimensions. The main weakness is the vague data availability statement, which lacks a concrete access mechanism. Minor reporting gaps include unspecified statistical software and lack of explicit CONSORT adherence.
Both reviewers agreed on study type (interventional). The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal-related criteria, code sharing). The statistics verification checked only 1 test (limited coverage), and the citation check found no retracted or missing references. The reviewers diverged on data code availability (pass vs. warn) and on a few sub-criteria (limitations addressed, outlier handling), which were resolved by weighing the evidence.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.
- CONSISTENTreported p = .002 · recomputed p = .002Reviewers 1, 2Primary endpoint pCR rate comparison (nivolumab vs placebo) using Cochran-Mantel-Haenszel test.
“A statistically significantly higher proportion of patients who received nivolumab achieved pCR (ypT0/is, ypN0; 24.5%, 63 of 257) versus placebo (13.8%, 35 of 253; odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”
Taken as given: The 63 and 35 are the event counts in the nivolumab and placebo arms, respectively.; The 257 and 253 are the total numbers in each arm.; The test is two-sided and uses a chi-square approximation to the Cochran-Mantel-Haenszel test.; The p-value is for the difference in pCR rates, not the odds ratio.Method: Recomputed the two-sided p-value using a chi-square test on the 2x2 table of pCR counts.How we recomputed it: pChi2x2(63, 257-63, 35, 253-35)
- lowinternal contradictionThe abstract states 'Of the five deaths that occurred in the nivolumab arm, two were related to study drug toxicity; no deaths occurred in the placebo arm.' However, the Results section reports three grade 5 treatment-unrelated events and two further deaths related to study drug toxicity, totaling five deaths. This is consistent, but the abstract's phrasing could be clearer.
“Of the five deaths that occurred in the nivolumab arm, two were related to study drug toxicity; no deaths occurred in the placebo arm.”
AbstractFind in source - lowinternal contradictionTable 1 shows PD-L1+ counts for placebo as 84, but the text says 'PD-L1+ tumors (PD-L1-expressing tumor-infiltrating immune cells (IC) ≥ 1% IC, n = 172)' which sums 88+84=172, consistent. However, the table footnote says 'PD-L1+ defined as PD-L1 IC ≥1%' and the column header shows 'SP142 PD-L1+ ( n = 84) a' which is consistent.
“SP142 PD-L1+ ( n = 84) a”
Table 1Find in source - lowinternal contradictionThe paper reports that 830 patients were screened and 521 were randomized, but the mITT population is 510. The exclusion of 11 patients due to Russian site closure is explained, but the difference between 521 and 510 is 11, which is consistent. However, the safety population is 517, which is not explained in the text.
Of the 830 patients screened, 521 were randomized. Because of the sponsor’s decision to close all sites in Russia after the Ukraine–Russia geopolitical conflict began, 11 patients were excluded from the analysis population because of insufficient follow-up for pCR assessment. The resulting population formed the modified intent-to-treat population (mITT), which comprised 510 patients ... The safety population consisted of the 517 patients who received neoadjuvant CT
Resultsreviewer’s wording
Overstated conclusions
4 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions overstated beyond the evidenceAssessed
- Conclusions only partially backed by the presented evidenceAssessed
8 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).
- overstatedReviewer 1The results suggest a new treatment paradigm that emphasizes the role of immunotherapy in luminal disease.While the pCR improvement is significant, the long-term benefit (EFS) is not established due to short follow-up and the exploratory nature of EFS. Calling it a 'new treatment paradigm' may be premature.Evidence: The paper itself acknowledges the study was underpowered for EFS and follow-up was short.
“These findings reshape our understanding of this disease in the context of T cell immunosurveillance and immunotherapy response in luminal disease.”
DiscussionFind in source - overstatedReviewer 2The results suggest a new treatment paradigm emphasizing the role of immunotherapy in luminal disease.The claim of a 'new treatment paradigm' is strong given the short follow-up and exploratory EFS; the paper itself notes longer follow-up is needed.Evidence: The paper discusses the results as a 'new milestone' but also notes limitations.
“These results represent a new milestone in the neoadjuvant treatment of ER+/HER2− BC”
DiscussionFind in source - partialReviewer 2The increase in pCR was associated with immune-related biomarkers and estrogen receptor expression.The paper shows associations with sTIL and PD-L1, and with ER/PR expression, but the multivariable analysis is exploratory and not adjusted for multiplicity.Evidence: Multivariable analysis showed sTIL and PD-L1 independently associated with nivolumab efficacy; pCR rates higher in lower ER/PR tumors.
“sTIL percentage (>1% or ≥5%) and PD-L1 (defined as IC ≥1% or CPS ≥3) were independently associated with nivolumab efficacy”
ResultsFind in source - supportedReviewers 1, 2Adding nivolumab to neoadjuvant chemotherapy significantly increased pCR rates in high-risk, early-stage ER+/HER2- breast cancer.The primary endpoint was met with a statistically significant difference in pCR rates (24.5% vs 13.8%, P=0.0021).Evidence: Primary endpoint analysis in the mITT population.
“Adding nivolumab to neoadjuvant chemotherapy significantly increased pCR rates in high-risk, early-stage ER+/HER2− BC”
AbstractFind in source - supportedReviewer 1The benefit of nivolumab is greater in patients with PD-L1-positive tumors.Subgroup analysis shows a larger absolute difference in pCR rates for PD-L1+ tumors (24.1%) compared to PD-L1- tumors (3.6%).Evidence: Subgroup analysis by PD-L1 status (Figure 2c).
“The difference in pCR rates (95% CI) between the nivolumab arm and placebo arm was 24.1% (10.1 to 36.7) and 3.6% (−3.6 to 10.7) for PD-L1+ and PD-L1− tumors, respectively”
ResultsFind in source - supportedReviewer 1The benefit of nivolumab is greater in patients with higher stromal tumor-infiltrating lymphocyte levels.The paper reports increased pCR rates with nivolumab in patients with higher sTIL levels, and multivariable analysis shows sTIL is independently associated with efficacy.Evidence: Subgroup analysis by sTIL status and multivariable analysis.
“pCR and RCB 0 or I rates with nivolumab versus placebo increased in patients with higher sTIL levels”
ResultsFind in source - supportedReviewers 1, 2There were no new safety signals identified.The safety profile is consistent with known nivolumab toxicities, and the paper reports no new safety signals.Evidence: Safety analysis in the safety population.
“There were no new safety signals identified.”
AbstractFind in source - supportedReviewer 2The benefit was greater in patients with PD-L1-positive tumors.Subgroup analysis showed a larger absolute difference in pCR for PD-L1+ (24.1%) vs PD-L1- (3.6%).Evidence: pCR rates by PD-L1 status: 44.3% vs 20.2% for PD-L1+; difference 24.1% (95% CI 10.1-36.7).
“with greater benefit observed in patients with programmed death ligand 1-positive tumors (VENTANA SP142 ≥1%: 44.3% versus 20.2% respectively)”
AbstractFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary endpoint is pathological complete response (pCR), a surrogate for long-term clinical outcomes such as event-free survival (EFS). The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking pCR to EFS in this specific setting; it only mentions that pCR is associated with improved long-term outcomes in ER+/HER2− BC, but this is not a validated surrogate for the efficacy claim.
“The primary endpoint of pCR was significantly higher in the nivolumab arm compared with placebo (24.5% versus 13.8%; P = 0.0021)”
- INADEQUATEEffect sizeThe effect size is reported as an absolute difference of 10.7% in pCR rates (24.5% vs 13.8%), which is statistically significant but not anchored to a minimal clinically important difference or to long-term clinical benefit. The paper acknowledges that the study is underpowered for EFS and that follow-up is too short to draw conclusions, so the clinical meaningfulness of the pCR improvement is not established.
“Because of its early termination, the study was significantly underpowered for event-free survival (EFS), and median follow-up for EFS in the mITT population at reporting was premature at 19 months, with a low number of events observed.”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
1 finding · worst mediumRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data/code availability incompleteAssessed
The introduction cites prior research on ER+/HER2- breast cancer heterogeneity, the role of lymphocytic infiltration, and results from I-SPY2 and KEYNOTE-756, providing a strong foundation. The hypothesis that adding anti-PD-1 to chemotherapy increases pCR rates is logically derived from this evidence. Limitations of prior research are implicitly addressed by the trial's design and biomarker analyses.
“ER+/HER2− BC exhibits significant heterogeneity in its responses to treatment and clinical outcomes, posing substantial challenges for effective management.”
“We hypothesized that addition of an anti-programmed death 1 agent may increase pCR rates in this BC subtype.”
“Results from the adaptively randomized I-SPY2 study suggest that anti-PD-(L)1 agents have the potential to increase the proportion of patients with high-risk ER+/HER2− BC who achieve pCR or minimal residual disease”
“ER+/HER2− BC exhibits significant heterogeneity in its responses to treatment and clinical outcomes, posing substantial challenges for effective management.”
“We hypothesized that addition of an anti-programmed death 1 agent may increase pCR rates in this BC subtype.”
“Results from the adaptively randomized I-SPY2 study suggest that anti-PD-(L)1 agents have the potential to increase the proportion of patients with high-risk ER+/HER2− BC who achieve pCR or minimal residual disease”
Randomization method (interactive response technology) and stratification factors are described. Blinding is double-blind, and the open-label adjuvant phase is explained. Power analysis is provided (87% power, 10% difference). Inclusion/exclusion criteria are detailed. Outlier handling is addressed via the mITT population and missing data due to site closure. Controls are the placebo arm. Independent replication is not applicable for a single pivotal trial.
“a sample size of 521 patients in the intent-to-treat population would yield approximately 87% power (two-sided alpha of 0.05) to detect a difference of 10% in pCR rates between treatment arms”
“CheckMate 7FL was a prospective, randomized, multicenter, double-blind, placebo-controlled phase 3 trial”
“Randomization was stratified per interactive response technology by the proportion of PD-L1-expressing immune cells (percentage of immune cells by VENTANA PD-L1 SP142 immunohistochemistry, cutoff at 1%), tumor grade (2 or 3), pathologically confirmed axillary nodal status (positive on pathological review or negative on radiographic and/or pathologic review) and anthracycline dosing frequency (every 3 weeks or every 2 weeks).”
“CheckMate 7FL was a prospective, randomized, multicenter, double-blind, placebo-controlled phase 3 trial”
“Based on the normal approximation to the binomial, a sample size of 521 patients in the intent-to-treat population would yield approximately 87% power (two-sided alpha of 0.05) to detect a difference of 10% in pCR rates between treatment arms, assuming a 12% pCR rate in the control arm.”
Sex is reported (all female in nivolumab arm, 99.6% in placebo). Age is reported with median and range. Health status is captured via ECOG PS. Demographics include tumor grade, stage, nodal status, and PD-L1 status. Species/strain and housing are not applicable for a human trial.
“Female | 257 (100) | 169 (100) | 88 (100) | 252 (99.6) | 168 (99.4) | 84 (100)”
“Median age, years (range) | 50 (24–78) | 51 (24–77) | 49 (28–78) | 51 (23–79) | 51 (23–79) | 51 (27–78)”
“Female | 257 (100) | 169 (100) | 88 (100) | 252 (99.6) | 168 (99.4) | 84 (100)”
“Median age, years (range) | 50 (24–78) | 51 (24–77) | 49 (28–78) | 51 (23–79) | 51 (23–79) | 51 (27–78)”
The trial protocol was approved by the appropriate ethics body at each participating site, and all patients provided written informed consent. Compliance with Good Clinical Practice is stated. The ethics statement is adequate as it names the approving bodies (ethics body at each site) and consent is described.
“The trial protocol and amendments were approved by the appropriate ethics body at each participating site.”
“All patients provided written informed consent.”
“All authors confirm that the trial was conducted with respect to the standards of Good Clinical Practice.”
“The trial protocol and amendments were approved by the appropriate ethics body at each participating site.”
“All patients provided written informed consent.”
“All authors confirm that the trial was conducted with respect to the standards of Good Clinical Practice.”
The investigational product (nivolumab) is identified with dose and regimen. The placebo is mentioned. Key assays (VENTANA SP142, Dako 28-8) are identified with manufacturers. Software tools are not explicitly named, but the statistical methods are described. Other bench resources are not applicable.
“patients were randomized 1:1 to receive either nivolumab 360 mg or placebo every 3 weeks with weekly paclitaxel for 12 weeks.”
“PD-L1 was evaluated by qualitative immunohistochemistry on immune cells with the VENTANA SP142 assay (Roche Diagnostics) and PD-L1 CPS with the 28-8 pharmDx assay (Agilent).”
“patients were randomized 1:1 to receive either nivolumab 360 mg or placebo every 3 weeks with weekly paclitaxel for 12 weeks.”
“PD-L1 was evaluated by qualitative immunohistochemistry on immune cells with the VENTANA SP142 assay (Roche Diagnostics) and PD-L1 CPS with the 28-8 pharmDx assay (Agilent).”
“ER and Ki67 expression were centrally evaluated using Agilent MIB-Dako pharmDx immunohistochemistry.”
Tests are named (Cochran-Mantel-Haenszel, Mantel-Haenszel, Clopper-Pearson, Newcombe). Exact p-values are reported (P = 0.0021). Effect sizes with CIs are provided (OR 2.05, 95% CI 1.29-3.27). Software is not identified, but this is a minor omission. Data presentation includes forest plots and CIs. Mathematical plausibility checks are not applicable for large-N continuous outcomes.
“Strata-adjusted difference in pCR rate between the two arms was analyzed with the stratified Cochran–Mantel–Haenszel method of weighting with a two-sided alpha level of 0.05.”
“odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”
“odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”
“Strata-adjusted difference in pCR rate between the two arms was analyzed with the stratified Cochran–Mantel–Haenszel method of weighting with a two-sided alpha level of 0.05.”
“24.5%, 63 of 257) versus placebo (13.8%, 35 of 253; odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”
“odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”
The data availability statement says Bristol Myers Squibb will honor legitimate requests for clinical trial data from qualified researchers, but does not specify a platform or timeframe. This is reported_but_inadequate. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.
“Bristol Myers Squibb will honor legitimate requests for clinical trial data from qualified researchers with a clearly defined scientific objective.”
“Bristol Myers Squibb will honor legitimate requests for clinical trial data from qualified researchers with a clearly defined scientific objective.”
The trial is registered (NCT04109066). Methods are detailed. Limitations are discussed (underpowered EFS, protocol amendment). Conclusions are proportional, acknowledging the need for longer follow-up. Funding and competing interests are disclosed. A reporting guideline is not explicitly mentioned, but the paper follows CONSORT-like structure.
“Clinical trials.gov identifier: NCT04109066”
“Limitations include the major protocol amendment that significantly reduced the sample size and/or number of events and follow-up time resulting in EFS being designated as an exploratory endpoint.”
“This study was sponsored and funded by Bristol Myers Squibb”
“Clinical trials.gov identifier: NCT04109066 (https://clinicaltrials.gov/study/NCT04109066)”
“Limitations include the major protocol amendment that significantly reduced the sample size and/or number of events and follow-up time resulting in EFS being designated as an exploratory endpoint.”
“This study was sponsored and funded by Bristol Myers Squibb”
Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 33 references by DOI: 31 verified — 2 no DOI (shown, not verified).
- NO DOICorrelation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPhase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
2 data/code links checked; 2 live.
- datahttps://clinicaltrials.gov/study/NCT04109066LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttps://clinicaltrials.gov/ct2/show/NCT04109066LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
6 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 6 minor suggestions below.
6 copyedit issues flagged: mostly consistency, clarity, typo.
- MINORconsistencyAbstract“Clinical trials.gov identifier”→ Change to 'ClinicalTrials.gov identifier' for consistency with standard usage.Capitalization inconsistency.
- MINORconsistencyResults, Efficacy“PD-L1+ tumors (PD-L1-expressing tumor-infiltrating immune cells (IC) ≥ 1% IC, n = 172)”→ Clarify the definition of PD-L1+ to avoid redundancy.Minor wording redundancy.
- MINORclarityMethods, Trial design and treatments“The combination of abemaciclib with nivolumab was expected to result in a high rate of withdrawals because of safety concerns around combining a CDK4/6 inhibitor with an anti-programmed death 1 agent”→ Consider adding a reference for this safety concern.Unsupported statement without citation.
- MINORconsistencyAbstract“Clinical trials.gov identifier”→ Change to 'ClinicalTrials.gov identifier'Inconsistent capitalization of 'Trials'.
- MINORtypoResults, Study population“Because of the sponsor’s decision to close all sites in Russia after the Ukraine–Russia geopolitical conflict began, 11 patients were excluded from the analysis population because of insufficient follow-up for pCR assessment.”→ Consider rephrasing for clarity.Long sentence but not an error.
- MINORconsistencyTable 1“PD-L1 b | <1% | 169 (66) | – | – | 169 (67) | – | – | ≥1% | 88 (34) | 84 (33)”→ Ensure the table formatting is consistent.The table appears to have missing cells for the placebo PD-L1+ column.
The published work is robust and generally well-reported, but an informed reader should weigh the vague data availability statement and the lack of explicit statistical software identification. The claim of a 'new treatment paradigm' is somewhat overstated given the short follow-up and exploratory EFS; a correction or clarification may be warranted. No critical validity threats were identified.
- 1.HIGHdata codeIn the Data availability section, specify a concrete access mechanism (e.g., a data-sharing platform like Vivli or a data access committee) and the timeframe for responding to requests.The current statement is vague and does not provide a clear route for qualified researchers to obtain the data, which is a reporting gap.
- 2.HIGHreportingIn the Discussion, temper the claim of a 'new treatment paradigm' to reflect that long-term benefit (EFS) is not yet established due to short follow-up and the exploratory nature of EFS.The claim is overstated given the evidence; the paper itself notes longer follow-up is needed.
- 3.MEDIUMreportingIn the Methods, explicitly name the statistical software (e.g., SAS version, R version) used for analyses.This improves reproducibility and was flagged by both reviewers as a minor omission.
- 4.MEDIUMreportingIn the Methods or Reporting Summary, explicitly state adherence to CONSORT guidelines for reporting randomized trials, or provide the completed CONSORT checklist.This strengthens the reporting transparency and is a common expectation for RCTs.
- 5.MEDIUMreportingIn the Discussion, add a sentence acknowledging the lack of independent replication of the biomarker findings.This addresses the limitations_addressed criterion and provides a more balanced interpretation.
- 6.MEDIUMreportingIn the Methods, clarify how outliers or missing data were handled in the analysis (e.g., imputation methods) beyond the exclusion of 11 patients due to site closure.This strengthens the outlier_handling criterion and transparency.
- 7.MEDIUMdata codeIn the Data availability section, mention whether the study protocol and statistical analysis plan are available in a public repository.This would allow independent verification of pre-specified analyses.
- 8.MEDIUMreportingIn the Results, report the number of patients with missing biomarker data for each assay to enhance transparency.This helps readers assess potential bias in biomarker analyses.
- 9.LOWcopyeditIn the Abstract, change 'Clinical trials.gov identifier' to 'ClinicalTrials.gov identifier' for consistency.Minor capitalization inconsistency flagged by the copyedit pass.
- 10.LOWcopyeditIn the Methods, add a reference for the safety concern about combining abemaciclib with nivolumab.The statement is unsupported without a citation.
- 11.LOWcopyeditIn Table 1, ensure the formatting is consistent, particularly the PD-L1+ columns for the placebo arm.The table appears to have missing cells, which could confuse readers.
- 12.LOWcopyeditIn the Results, clarify the definition of PD-L1+ tumors to avoid redundancy.Minor wording redundancy flagged by the copyedit pass.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.